Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06971276 · ClinicalTrials.gov registry record
Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening
A clinical trial of Anal Dysplasia, sponsored by Massachusetts Eye and Ear Infirmary.
- Active
- Registry status
- 101
- Enrollment target
- 1
- Study location
NCT06971276: Active study of Anal Dysplasia, sponsored by Massachusetts Eye and Ear Infirmary.
NCT06971276 is a study of Anal Dysplasia that is active but no longer recruiting, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 101 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06971276, a study of Anal Dysplasia, is active but no longer recruiting, sponsored by Massachusetts Eye and Ear Infirmary.
- ACTIVE NOT RECRUITING
- Registry status
- 101 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is to test a liquid biopsy assay for screening and classifying anal dysplasia from blood.
Primary Outcome
Anal dysplasia screening results based on tissue biopsy collected at time of the visit or clinical diagnosis when biopsy is not available.
Conditions Studied
Study Locations (1)
Massachusetts
- Department of Infectious Diseases, Mass General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2024-04-03 |
| Est. Completion | 2026-01-31 |
What the registry record for NCT06971276 still lists
NCT06971276 is an observational study that tracks outcomes without assigning an intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Anal Dysplasia appearing as the primary indexed condition, and to 0 interventions.
NCT06971276 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06971276 about?
NCT06971276 is a clinical study titled "Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening". The study is to test a liquid biopsy assay for screening and classifying anal dysplasia from blood.
What is the current status of trial NCT06971276?
This trial is currently active not recruiting. The enrollment target is 101 participants. The study started on 2024-04-03. Estimated completion is 2026-01-31.
What conditions does trial NCT06971276 study?
This clinical trial studies the following conditions: Anal Dysplasia.
Who is sponsoring clinical trial NCT06971276?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06971276 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anal Dysplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI